Trial of Vision Therapy for Intermittent Exotropia

NCT ID: NCT04487249

Last Updated: 2025-03-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

58 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this randomized trial comparing vision therapy to observation is to determine the short-term effectiveness of vision therapy on distance intermittent exotropia control. The results will help determine whether to proceed to a full-scale, long-term randomized trial.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Vision therapy (VT) is a commonly prescribed treatment for children with intermittent exotropia (IXT). The effectiveness of VT as a treatment modality for children with IXT is unknown because previous studies have largely limited observational or retrospective case series without comparison groups. The objective of this multi-centered pilot randomized trial of VT for IXT compared to observation is to 1) determine the short-term effectiveness of VT on distance intermittent exotropia and 2) determine the feasibility of recruitment and retention of children aged 8 to 16 years old with IXT to participate in a randomized trial of 20 weeks of in-office VT. The results of this trial will provide the needed information to plan and conduct a large-scale randomized trial to determine short-term and long-term effectiveness of VT for IXT in children, with the full-scale randomized trial helping to fill in the gaps in scientific knowledge concerning VT as a treatment for IXT.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intermittent Exotropia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vision Therapy

Participants will receive 20 consecutive weeks of office-based vision therapy with home therapy.

Group Type EXPERIMENTAL

Vision Therapy

Intervention Type OTHER

20 consecutive weeks of office-based vision therapy with home therapy that aim to improve the participant's vergence skills, accommodative skills, and sensory fusion.

Observation

Participants will receive no treatment for IXT is received during the study unless one of the deterioration criteria is met.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vision Therapy

20 consecutive weeks of office-based vision therapy with home therapy that aim to improve the participant's vergence skills, accommodative skills, and sensory fusion.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Orthoptics

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 8 - 16 years
* Intermittent exotropia meeting all of the following:

* Distance exodeviation of 15∆ to 35∆ by prism alternating cover test (PACT)
* IXT, exophoria, or orthophoria at near
* Near exodeviation that does not exceed the distance exodeviation by more than 10∆
* Mean distance control score of 2 points or more with at least one measure being 3 points or higher
* Mean near control score less than 5 points
* Random dot stereopsis of 200" or better on Preschool Randot Stereotest
* Willingness to accept randomization and no plan to relocate in the next 6 months

Exclusion Criteria

* Treatment for IXT or amblyopia (other than refractive correction) within 3 months prior to enrollment
* Office-based vision therapy for IXT within 6 months prior to enrollment
* Prior office-based vision therapy for IXT of ≥10 sessions
* Prior strabismus, intraocular, or refractive surgery (including BOTOX injection)
Minimum Eligible Age

8 Years

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Stanford University

OTHER

Sponsor Role collaborator

Ohio State University

OTHER

Sponsor Role collaborator

Salus University

OTHER

Sponsor Role collaborator

University of Alabama at Birmingham

OTHER

Sponsor Role collaborator

Southern College of Optometry

OTHER

Sponsor Role collaborator

Case Western Reserve University

OTHER

Sponsor Role collaborator

American Academy of Optometry

OTHER

Sponsor Role collaborator

Southern California College of Optometry at Marshall B. Ketchum University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Angela Chen, OD, MS

Role: STUDY_CHAIR

Southern California College of Optometry at Marshall B. Ketchum University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama in Birmingham

Birmingham, Alabama, United States

Site Status RECRUITING

Southern California College of Optometry at Marshall B. Ketchum University

Fullerton, California, United States

Site Status RECRUITING

Stanford University

Stanford, California, United States

Site Status RECRUITING

Ohio State University

Columbus, Ohio, United States

Site Status RECRUITING

Salus University

Philadelphia, Pennsylvania, United States

Site Status RECRUITING

Southern College of Optometry

Memphis, Tennessee, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Angela Chen, OD, MS

Role: CONTACT

714-463-7569

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kristine Hopkins, OD, MSPH

Role: primary

205-996-1678

Angela Chen, OD, MS

Role: primary

714-463-7569

Tawna Roberts, OD, PhD

Role: primary

650-723-1143

Ann Morrison, OD, MS

Role: primary

614-247-0010

Erin Jenewein, OD, MS

Role: primary

215-276-6053

Marie Bodack, OD

Role: primary

901-722-3349

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20-08

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.